Innovative chiral resolution using enantiospecific cocrystallization in solution

A large number of active pharmaceutical ingredients (API) are chiral. Most of them are synthesized as racemic mixtures, and a chiral resolution step is introduced somewhere along the production process. In this study, we have used the specific hydrogen bonding interactions present in co-crystals to develop a new resolution technique. As these interactions are strongly direction dependent, we highlighted that an enantiopure API only forms a co-crystal with one of two enantiomers of a chiral co-crystal former (or co-former). Unlike salts, a diastereomeric pair cannot be obtained. This enantiospecific behavior of co-crystal candidates suggests that a racemic mixture of this candidate can be resolved through a co-crystallization in solution, which hitherto has not been observed yet. As a study system, we chose (RS)-2-(2-oxopyrrolidin-1-yl)butanamide, as the S-enantiomer is an API and no viable salts of this compound have been identified. The only known resolution technique for this compound is, therefore, based on chiral chromatography. Because of enantiospecific interactions with an S-mandelic acid coformer, we were able to selectively co-crystallize the S-enantiomer in acetonitrile. This enantiospecific co-crystallization in solution has been thermodynamically verified, by construction of ternary phase diagrams at different temperatures. Initial results not only validate our innovative resolution technique through co-crystallization but also furthermore already showed high efficiency, as 70% of the S-enantiomer could be separated from the racemic mixture in a single co-crystallization step.

[1]  H. Brittain.  Vibrational Spectroscopic Studies of Cocrystals and Salts. 4. Cocrystal Products formed by Benzylamine, α-Methylbenzylamine, and their Chloride Salts , 2011 .

[2]  Josemir W Sander,et al.  The impact of levetiracetam on challenging behavior , 2006, Epilepsy & Behavior.

[3]  T. Leyssens,et al.  A new approach for the estimation of the melting enthalpy of metastable crystalline compounds using differential scanning calorimetry , 2012, Journal of Thermal Analysis and Calorimetry.

[4]  G. Egri,et al.  Optical resolution methods. , 2006, Organic & biomolecular chemistry.

[5]  A. Newman,et al.  Pharmaceutical Cocrystals and Their Physicochemical Properties , 2009, Crystal growth & design.

[6]  T. Leyssens,et al.  Advances in pharmaceutical Co-crystal screening: Effective Co-crystal screening through structural resemblance , 2012 .

[7]  M. Neuburger,et al.  Piracetam Co-Crystals with OH-Group Functionalized Carboxylic Acids , 2009 .

[8]  T. Leyssens,et al.  Towards the Determination of the Solubilities of the Two Enantiotropically Related Crystallographic Forms of Etiracetam in Methanol , 2011 .

[9]  M. Bialer,et al.  Pharmacokinetics of Levetiracetam and Its Enantiomer (R)‐α‐ethyl‐2‐oxo‐pyrrolidine acetamide in Dogs , 2001, Epilepsia.

[10]  G. Blaschke,et al.  Resolution of Enantiomers of Chiral Drugs , 2000 .

[11]  Stephen Stinson,et al.  CHIRAL PHARMACEUTICALS: Drug firms continue to develop chiral drugs as single enantiomers, to carry out racemic switches, and to use chirality to manage drug life cycles , 2001 .

[12]  N. Candoni,et al.  Importance of Solvent Selection for Stoichiometrically Diverse Cocrystal Systems: Caffeine/Maleic Acid 1:1 and 2:1 Cocrystals , 2012 .

[13]  N. Srinivas.  Evaluation of experimental strategies for the development of chiral chromatographic methods based on diastereomer formation. , 2004, Biomedical chromatography : BMC.

[14]  Shengyong Zhang,et al.  Investigation of Enantiomeric Separation of Chiral Drugs by CE Using Cu(II)–Clindamycin Complex as a Novel Chiral Selector , 2011 .

[15]  Geoff G. Z. Zhang,et al.  Chiral co-crystal solid solution: structures, melting point phase diagram, and chiral enrichment of (ibuprofen)2(4,4-dipyridyl) , 2010 .

[16]  Peddy Vishweshwar,et al.  Pharmaceutical co-crystals. , 2006, Journal of pharmaceutical sciences.

[17]  T. Leyssens,et al.  Use of in Situ Raman, FBRM, and ATR-FTIR Probes for the Understanding of the Solvent-Mediated Polymorphic Transformation of II–I Etiracetam in Methanol , 2012 .

[18]  William Jones,et al.  Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement , 2006 .

[19]  K. Lyseng-Williamson.  Levetiracetam: a review of its use in epilepsy. , 2011, Drugs.

[20]  T. Leyssens,et al.  Detection of the II–I Etiracetam solvent-mediated polymorphic transformation through the online monitoring of the suspension apparent viscosity , 2012 .

[21]  K. Fan,et al.  Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery: building chiral technology toolboxes. , 2007, Chirality.

[22]  T. Leyssens,et al.  Towards an accurate and precise determination of the solid―solid transition temperature of enantiotropic systems , 2011 .

[23]  Ning Shan,et al.  The role of cocrystals in pharmaceutical science. , 2008, Drug discovery today.

[24]  A. Sudalai,et al.  A short enantioselective synthesis of the antiepileptic agent, levetiracetam based on proline-catalyzed asymmetric α-aminooxylation , 2006 .

[25]  B. Simándi,et al.  Co-crystal of (R,R)-1,2-cyclohexanediol with (R,R)-tartaric acid, a key structure in resolution of the (±)-trans-diol by supercritical extraction, and the related ternary phase system , 2010 .

[26]  Miranda L. Cheney,et al.  Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine , 2010 .

[27]  J. H. T. Horst,et al.  Racemic Compound, Conglomerate, or Solid Solution: Phase Diagram Screening of Chiral Compounds , 2010 .